Crossovers remain a top pick for millions of consumers, and the 2025 Toyota Corolla Cross maintains its appeal with a ...

The Toyota Corolla is a legend in the realm of practical cars for reasonable money with a reputation for reliability. On sale ...

One hybrid vehicle (HEV) is a pretty popular model that many people may know about: the Toyota Corolla Hybrid. If you're wondering which model offers the best reliability and its general basics ...

Toyota South Africa Motors (TSAM) is immensely proud of the Corolla Cross, with good reason. The crossover has breathed new life into the iconic Corolla nameplate, has become a very strong seller (22 ...

Dive in to see what’s new with every 2025 Toyota SUV. Considering the Corolla Cross made its debut for 2022, this small SUV should receive a midcycle face-lift soon. Whether that will arrive ...

The facelifted version of Toyota's highly successful Corolla Cross has made its official debut at the company's State of the Motor Industry (SOMI) event in Johannesburg. The updated cross receives ...

The Toyota Corolla has been one of the world's best-selling cars for nearly 60 years and continues to maintain its reputation for reliability, affordability, and safety in 2025. While its ...

The Corolla is a fine family car with hybrid engines that offer very low running costs Timing is everything, and it’s entirely possible that the latest Toyota Corolla arrived at a vital point ...

The facelifted Toyota Corolla Cross has launched in South Africa. Here’s a look at pricing for the updated locally built crossover, which gains fresh exterior styling and more kit… Almost a year ago, ...

Having arrived in 1951 as the Toyota Jeep BJ (and adopted the Land Cruiser name in 1955), by 1967 Toyota had realised it could be more than a hardcore workhorse and created the Station Wagon line ...

Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels ...

If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix’s successful urology ...